|Dr. Seth Lederman M.D.||Co-Founder, Pres, CEO & Chairman||472.5k||N/A||60|
|Mr. Bradley Saenger CPA||CFO & Treasurer||301.36k||N/A||44|
|Dr. Gregory M. Sullivan M.D.||Chief Medical Officer & Sec.||335k||N/A||52|
|Mrs. Jessica Edgar Morris||Exec. VP of Operations||N/A||N/A||N/A|
|Dr. Ronald R. Notvest Ph.D., MBA||Exec. VP of Commercial Planning and Devel.||N/A||N/A||N/A|
Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. Its lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Tonix Pharmaceuticals Holding Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.